BimekizumabMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3500011/fr/bimzelx-bimekizumab-psoriasis-en-plaques
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
injections, subcutaneous
bimekizumab
evaluation of the transparency committee
psoriasis
bimekizumab

---
https://www.has-sante.fr/jcms/p_3539120/fr/bimzelx-bimekizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
bimekizumab
chronic disease
biological therapy
injections, subcutaneous

---
https://www.has-sante.fr/jcms/p_3562973/fr/bimzelx-bimekizumab-hidradenite-suppuree-maladie-de-verneuil
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
bimekizumab
Interleukin-17A
Interleukin-17F
Interleukin Inhibitors
adult
evaluation of the transparency committee
hidradenitis suppurativa
bimekizumab

---
https://www.has-sante.fr/jcms/p_3422860/fr/bimzelx-bimekizumab-psoriasis-en-plaques
2023
false
false
false
France
bimekizumab
treatment outcome
insurance, health, reimbursement
adult
injections, subcutaneous
evaluation of the transparency committee
bimekizumab
psoriasis

---
https://www.has-sante.fr/jcms/p_3323505/fr/bimzelx-bimekizumab
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
adult
psoriasis
bimekizumab
Interleukin Inhibitors
injections, subcutaneous
chronic disease
evaluation of the transparency committee
bimekizumab

---
https://www.has-sante.fr/jcms/p_3336645/fr/bimzelx-bimekizumab
https://www.has-sante.fr/jcms/p_3336651/fr/decision-n-2022-0147/dc/sem-du-28-avril-2022-du-college-de-la-haute-autorite-de-sante-portant-refus-de-la-demande-d-acces-precoce-de-la-specialite-bimzelx
2022
false
false
false
France
French
evaluation of the transparency committee
bimekizumab
bimekizumab

---
https://www.cadth.ca/fr/bimekizumab
2021
false
false
false
Canada
French
canada
drug evaluation
bimekizumab
psoriasis
adult
bimekizumab
antibodies, monoclonal, humanized

---
https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
bimekizumab
bimekizumab
adult
psoriasis
injections, subcutaneous
Interleukin-17A
Interleukin-17F
Interleukin Inhibitor
Interleukin Inhibitor
bimekizumab
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
aged
drug evaluation, preclinical

---